Irving, United States, 16th November 2022 / Sciad Newswire / Darling Ingredients’ Health Brand, Rousselot, the global leader in collagen-based solutions, and Gelomics, the world-leading provider of fully integrated 3D cell, organoid and tissue culture technologies, have entered into a cobranding partnership. Rousselot Biomedical will supply Gelomics with its X-Pure GelMA (gelatin methacryloyl), a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel™ 3D Tissue Culture System.
GelMA is a well-known biomaterial with tuneability and bioactivity that is used in a wide range of tissue engineering, 3D bioprinting and 3D cell culture applications. Rousselot’s X-Pure GelMA is ultra-pure (<10 Endotoxin Units (EU)/g), and the first GelMA to be produced under GMP conditions. The new LunaGel X-Pure gelatin product series will be available as ready-to-use kits in low and high stiffness formulations, providing the world’s first premium, ultra-pure GelMA in an easy-to-use format.
“We are proud to partner with Gelomics, who share our passion and commitment to quality and collaboration,” said Tanja Vervust, Director Rousselot Biomedical. "Leveraging the consistency and purity of X-Pure GelMA, the LunaGel X-Pure products offer Gelomics’ customers an easy-to-use solution for creating the optimal experimental conditions for cell culture.”
Christoph Meinert, CEO of Gelomics, said, “The broad uptake of modern 3D cell culture techniques in biomedical R&D has been slowed down by a lack of easy-to-use and reproducible biomaterials that enable cells to grow and behave in a physiological manner. We are pleased to partner with Rousselot Biomedical to overcome these limitations and provide the world’s first, ready-to-use 3D cell culture kits based on Rousselot Biomedical’s X-Pure GelMA.”
Launched earlier this year, Rousselot Biomedical's co-branding program brings together innovative biotechnology companies and Rousselot's expertise in biomedical gelatins to advance the development of new medicines and medical devices.
Darling Ingredients established Rousselot Biomedical in 2018 to develop ultra-pure gelatin and collagen solutions for biomedical applications ranging from vaccines to hemostats to regenerative medicines. Today, Rousselot Biomedical is a partner of choice for biomedical research companies, start-ups and industries in search of medical grade gelatin with outstanding levels of purity for research and in-body applications.
Founded in 2018 in Australia, Gelomics has rapidly become a world-leading provider of fully integrated 3D cell, organoid and tissue culture technologies. Gelomics fast tracks biomedical research and development by enabling researchers to grow human-like tissues in the laboratory that drastically improve the translational value of cell-based research and reduce the requirements for animal experimentation.
Notes to Editors
Gelomics is a world-leading provider of fully integrated 3D cell, organoid, and tissue culture technologies. Gelomics’ first product series, LunaGel™ is a photocrosslinkable cell culture system that recreates the natural extracellular matrix (ECM) surrounding cells in the human body, allowing researchers to grow three-dimensional microscopic tissues, rather than just cells on plastic surfaces. The unique LunaGel™ photocrosslinking technology enables the rapid generation of highly biomimetic extracellular microenvironments with the largest range of mechanical tuneability on the market, enabling scientists to replicate the properties of various healthy and diseased tissues.
About Darling Ingredients
Darling Ingredients Inc. (NYSE: DAR) is the largest publicly traded company turning edible by-products and food waste into sustainable products and a leading producer of renewable energy. Recognized as a sustainability leader, the company operates more than 250 plants in 17 countries and repurposes approximately 15% of the world's meat industry waste streams into value-added products, such as green energy, renewable diesel, collagen, fertilizer, animal proteins and meals and pet food ingredients. To learn more, visit darlingii.com and follow us on LinkedIn.
About Rousselot Biomedical
As the most recent strategic segment within Rousselot, Darling Ingredients’ Health Brand, we have drawn upon Rousselot’s 130+ years of worldwide expertise and proven track record of pharmaceutical gelatins and collagens to develop innovative ranges of purified, modified and non-modified gelatins and collagens for biomedical applications. Offering unique advantages to assure performance, quality and safety from bench to clinic, Rousselot X-PURE® and Rousselot QUALI-PURE® are backed by strong scientific data and ongoing research. Rousselot Biomedical is committed to supporting end-to-end partnerships to help “Advancing medical science”. www.rousselot.com/biomedical
For further information, please contact:
Director of Communications & PR, Rousselot
Maria Patey / Sophie Protheroe
T: +44 (0)20 3405 7892